Chemical Information | |
Antiviral agent ID | DrugRepV_2136 | |
Antiviral agent name | 7-deaza-2-C-methyl-D-adenosine | |
IUPAC Name | (2R,3R,4R,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol | |
SMILES (canonical) | CC1(C(C(OC1N2C=CC3=C2N=CN=C3N)CO)O)O | |
SMILES (isomeric) | C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C2N=CN=C3N)CO)O)O | |
Molecular Formula | C12H16N4O4 | |
Molecular Weight (g/mol) | 280.284 | |
InChl | InChI=1S/C12H16N4O4/c1-12(19)8(18)7(4-17)20-11(12)16-3-2-6-9(13)14-5-15-10(6)16/h2-3,5,7-8,11,17-19H,4H2,1H3,(H2,13,14,15)/t7-,8-,11-,12-/m1/s1 | |
Structural Information | |
|
|
Clinical Information | |
Biological Information | |
Primary Indication (Disease Category) | Infectious Disease
| |
Primary Indication (Disease) | Viral infection
| |
Secondary Indication | Zika virus (ZIKV) NA MR766 | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | in-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Vero
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Drug concentration) | 1.3 μM
| |
Secondary Indication (Cell based assay) | Plaque assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | EC50 [ 50 % ] | |
Reference | Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJ, Neyts J..The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika V.PLoS Negl Trop Dis. 2016 May 10;10(5):e0004695. doi: 10.1371/journal.pntd.0004695. eCollection 2016 PMID:27163257
| |
Comment | AG129 mice can generate an antibody response, and have been used in dengue vaccine studies, the model can also be used to assess the efficacy of ZIKV vaccines.
| |